For help on how to get the results you want, see our search tips.
5 results
Medicine type
Conditional approval Remove Conditional approval filter
Accelerated assessment Remove Accelerated assessment filter
Biosimilar Remove Biosimilar filter
Exceptional circumstances Remove Exceptional circumstances filter
Additional monitoring Remove Additional monitoring filter
Orphan medicine Remove Orphan medicine filter
Opinion status
Negative Remove Negative filter
-
List item
Summary of opinion: Trelegy Ellipta
fluticasone furoate, umeclidinium, vilanterol, opinion date: 25/02/2021, Negative, Last updated: 26/02/2021 -
List item
Summary of opinion: Elebrato Ellipta
fluticasone furoate, umeclidinium, vilanterol, opinion date: 25/02/2021, Negative, Last updated: 26/02/2021 -
List item
Summary of opinion: Temybric Ellipta
fluticasone furoate, umeclidinium, vilanterol, opinion date: 25/02/2021, Negative, Last updated: 26/02/2021 -
List item
Summary of opinion: Tuznue (new)
trastuzumab, opinion date: 19/05/2022, Negative, Last updated: 20/05/2022 -
List item
Summary of opinion: Hervelous (new)
trastuzumab, opinion date: 19/05/2022, Negative, Last updated: 20/05/2022